HEMLIBRA® is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with or without factor VIII inhibitors.
This bold, flexible graphic campaign highlights the unique MoA that mimics Factor VIII (F8) inhibitors, appealing to a very pragmatic scientific audience of experts who are attracted by efficacy and data rather than emotive imagery, separating Hemlibra even more from its competitors.
Additional materials included an online depository of videos from both HCPs and patient testimonials for a CRM platform and
a chatbot app acting as an innovative objection handler tool.
Alternative creative options presented at pitch stage
(click to enlarge)